Literature DB >> 3292209

Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

D M Campoli-Richards1, J P Monk, A Price, P Benfield, P A Todd, A Ward.   

Abstract

Ciprofloxacin is one of a new generation of fluorinated quinolones structurally related to nalidixic acid. The primary mechanism of action of ciprofloxacin is inhibition of bacterial DNA gyrase. It is a broad spectrum antibacterial drug to which most Gram-negative bacteria are highly susceptible in vitro and many Gram-positive bacteria are susceptible or moderately susceptible. Unlike most broad spectrum antibacterial drugs, ciprofloxacin is effective after oral or intravenous administration. Ciprofloxacin has been most extensively studied following oral administration. It attains concentrations in most tissues and body fluids which are at least equivalent to the minimum inhibitory concentration designated as the breakpoint for bacterial susceptibility in vitro. The results of clinical trials with orally and intravenously administered ciprofloxacin have confirmed the potential for its use in a wide range of infections, which was suggested by its in vitro antibacterial and pharmacokinetic profiles. It has proven an effective treatment for many types of systemic infections as well as for both acute and chronic infections of the urinary tract. Ciprofloxacin generally appeared to be at least as effective as alternative orally administered antibacterial drugs in the indications in which they were compared, and in some indications, to parenterally administered antibacterial therapy. However, further studies are needed to fully clarify the comparative efficacy of ciprofloxacin and standard antibacterial therapies. Bacterial resistance to ciprofloxacin develops infrequently, both in vitro and clinically, except in the setting of pseudomonal respiratory tract infections in cystic fibrosis patients. The drug is also well tolerated. Thus, as an orally active, broad spectrum and potent antibacterial drug, ciprofloxacin offers a valuable alternative to broad spectrum parenterally administered antibacterial drugs for use in a wide range of clinical infections, including difficult infections due to multiresistant pathogens.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3292209     DOI: 10.2165/00003495-198835040-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  357 in total

1.  The adverse effects of fluoroquinolones.

Authors:  C R Smith
Journal:  J Antimicrob Chemother       Date:  1987-06       Impact factor: 5.790

2.  Ciprofloxacin in the treatment of infections caused by gentamicin-resistant gram-negative bacteria.

Authors:  S Mehtar; Y Drabu; P Blakemore
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

3.  Treatment of chronic postsurgical osteomyelitis with ciprofloxacin.

Authors:  J A Hoogkamp-Korstanje
Journal:  Pharm Weekbl Sci       Date:  1987-12-11

4.  Ciprofloxacin and antacids.

Authors:  L C Preheim; T A Cuevas; J S Roccaforte; M A Mellencamp; M J Bittner
Journal:  Lancet       Date:  1986-07-05       Impact factor: 79.321

5.  Ciprofloxacin-resistant Pseudomonas.

Authors:  C M Roberts; J Batten; M E Hodson
Journal:  Lancet       Date:  1985-06-22       Impact factor: 79.321

6.  Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations.

Authors:  A L Barry; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1984-06       Impact factor: 5.191

7.  Crystalluria and ciprofloxacin, influence of urinary pH and hydration.

Authors:  S B Thorsteinsson; T Bergan; S Oddsdottir; R Rohwedder; R Holm
Journal:  Chemotherapy       Date:  1986       Impact factor: 2.544

8.  In vitro activities of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, M. avium complex, M. chelonei, M. fortuitum, and M. kansasii.

Authors:  J D Gay; D R DeYoung; G D Roberts
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

9.  Treatment of nongonococcal urethritis with ciprofloxacin.

Authors:  I W Fong; W Linton; M Simbul; R Thorup; B McLaughlin; V Rahm; P A Quinn
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

10.  Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis.

Authors:  M E Hodson; C M Roberts; R J Butland; M J Smith; J C Batten
Journal:  Lancet       Date:  1987-01-31       Impact factor: 79.321

View more
  88 in total

1.  Bioavailability prediction based on molecular structure for a diverse series of drugs.

Authors:  Joseph V Turner; Desmond J Maddalena; Snezana Agatonovic-Kustrin
Journal:  Pharm Res       Date:  2004-01       Impact factor: 4.200

2.  Effect of ciprofloxacin on antipyrine pharmacokinetics and metabolism in rats.

Authors:  A Anadón; M R Martinez-Larrañaga; M C Fernandez; M J Diaz; P Bringas
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

Review 3.  Treatment of genitourinary tract infections with fluoroquinolones: clinical efficacy in genital infections and adverse effects.

Authors:  D C Hooper; J S Wolfson
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

Review 4.  Treatment of genitourinary tract infections with fluoroquinolones: activity in vitro, pharmacokinetics, and clinical efficacy in urinary tract infections and prostatitis.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

5.  Distribution of ciprofloxacin in ascitic fluid following administration of a single oral dose of 750 milligrams.

Authors:  M Dan; T Zuabi; C Quassem; H H Rotmensch
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

6.  Survey: calculation of the characteristics of oral diffusion-controlled release dosage forms related to the drug.

Authors:  I D Rosca; J M Vergnaud
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2010-09       Impact factor: 2.441

7.  Comparative serum bactericidal activities of three doses of ciprofloxacin administered intravenously.

Authors:  M Dan; F Poch; C Quassem; R Kitzes
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

Review 8.  Ciprofloxacin. A review of its pharmacological profile and therapeutic use in the elderly.

Authors:  L R Wiseman; J A Balfour
Journal:  Drugs Aging       Date:  1994-02       Impact factor: 3.923

9.  The effect of ciprofloxacin on theophylline pharmacokinetics in healthy subjects.

Authors:  K T Batty; T M Davis; K F Ilett; L J Dusci; S R Langton
Journal:  Br J Clin Pharmacol       Date:  1995-03       Impact factor: 4.335

Review 10.  Pefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J P Gonzalez; J M Henwood
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.